Abata Therapeutics

Scientist, Functional Genomics

South San Francisco, California, United States

Not SpecifiedCompensation
Junior (1 to 2 years), Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, GeneticsIndustries

Requirements

The ideal candidate should possess a Ph.D. in Molecular Biology, Genetics, Pharmacology, or a related field, along with at least two years of industry experience. Familiarity with perturb-seq and single-cell genomics is required, as is the ability to troubleshoot technical issues, adapt to new protocols, and optimize methodologies for performing large-scale pooled screens. Excellent written and verbal communication skills, including a track record of presenting complex scientific results, are also necessary, alongside demonstrated success in collaborative, team-oriented environments.

Responsibilities

This role involves developing, implementing, and scaling high-throughput CRISPR-based screening protocols to uncover genotype-phenotype relationships at scale, driving continuous innovation in experimental workflows and screening methodologies, partnering with computational biology, AI/ML, and drug discovery teams to analyze and interpret functional genomics datasets, identifying and resolving challenges in data generation, independently managing multiple projects to ensure timely delivery of high-quality data, and maintaining accurate records of experiments and contributing to scientific presentations.

Skills

CRISPR
perturb-seq
single-cell genomics
troubleshooting
protocol optimization
data analysis
scientific communication
collaboration

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Key Metrics

Cambridge, MassachusettsHeadquarters
2021Year Founded
$184.8MTotal Funding
EARLY_VCCompany Stage
BiotechnologyIndustries
11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.
Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.
Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.
FDA's accelerated approval pathways may expedite Abata's clinical trials.
Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI